|Mr. John Rodney Varner||Co, Founder, Pres, CEO, Sec. & Chairman||429.68k||N/A||1957|
|Mr. Ryan M. Confer M.S.||Chief Financial Officer||341.71k||N/A||1982|
|Mr. Michael T. Redman||Exec. VP & COO||N/A||N/A||1955|
|Ms. Catherine M. Vaczy||Exec. VP, Gen. Counsel & Chief Strategy Officer||N/A||N/A||1961|
|Ms. Kalyn Dabbs||Sr. Mang. of Communications & Marketing||N/A||N/A||N/A|
|Mr. Thomas C. Gallagher Esq.||Sr. VP of Intellectual Property & Licensing||N/A||N/A||N/A|
|Dr. William E. Gannon Jr.||Member of Clinical Advisory Board & VP of Regulatory Affairs||N/A||N/A||N/A|
|Dr. Jack A. Roth F.A.C.S., FACS, M.D.||Chairman of Scientific & Medical Advisory Board||N/A||N/A||N/A|
Genprex, Inc. operates as a clinical-stage gene therapy company that develops treatments for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new treatment options for patient populations with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001), which is in preclinical stage for the treatment of non-small cell lung cancer (NSCLC). It is also developing GPX-002, a preclinical stage gene therapy for diabetes. The company also offers ONCOPREX, a nanoparticle delivery system. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
Genprex, Inc.’s ISS Governance QualityScore as of April 1, 2021 is 10. The pillar scores are Audit: 10; Board: 10; Shareholder Rights: 8; Compensation: 9.